Abstract
Acne is one of the most common dermatological conditions to affect women of childbearing age, so it is important to consider the safety of long-term acne treatments on women who could become pregnant. In this review article, we clarify what management options are available to treat acne during pregnancy. Topical treatments, typically first-line for acne, such as azelaic acid, clindamycin, erythromycin, metronidazole, benzoyl peroxide, salicylic acid, dapsone, and retinoids, were reviewed. Systemic treatments, such as zinc supplements, cephalexin, cefadroxil, amoxicillin, azithromycin, erythromycin, and corticosteroids, typically second-line for acne, were also reviewed. Alternative treatments such as light therapy and cosmetic procedures were also evaluated. Due to recommendation of sunscreen utilization during acne treatments, sunscreen usage during pregnancy was also assessed. Management of acne during unplanned pregnancy was discussed in further detail regarding safety and adverse effects. Through summarized tables and examples of studies demonstrating safety and efficacy of treatments, the following is a resource for providers and patients to utilize for management of acne during pregnancy.
Similar content being viewed by others
Data Availability
Not applicable.
References
Landis MN. Optimizing isotretinoin treatment of acne: update on current recommendations for monitoring, dosing, safety, adverse effects, compliance, and outcomes. Am J Clin Dermatol. 2020;21(3):411–9. https://doi.org/10.1007/s40257-020-00508-0.
Nussbaum R, Benedetto AV. Cosmetic aspects of pregnancy. Clin Dermatol. 2006;24(2):133–41. https://doi.org/10.1016/j.clindermatol.2005.10.007.
Bechstein SK, Ochsendorf F. Akne und Rosazea in der Schwangerschaft [Acne and rosacea in pregnancy]. Der Hautarzt Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2017;68(2):111–9. https://doi.org/10.1007/s00105-016-3918-8.
Kutlu Ö, Karadağ AS, Ünal E, Kelekçi KH, Yalçınkayaİyidal A, TopaloğluDemir F, Aksoy B, Çölgeçen E, Tosun M, Emre S, Tatlıparmak A, Demirseren DD, Kaya Özden H, Öztürk M, Özlü E, Chen W. Acne in pregnancy: a prospective multicenter, cross-sectional study of 295 patients in Turkey. Int J Dermatol. 2020;59(9):1098–105. https://doi.org/10.1111/ijd.14999.
Ly S, Kamal K, Manjaly P, Barbieri JS, Mostaghimi A. Treatment of acne vulgaris during pregnancy and lactation: a narrative review. Dermatol Ther. 2023;13(1):115–30. https://doi.org/10.1007/s13555-022-00854-3.
Blattner CM, Danesh M, Safaee M, Murase JE. Understanding the new FDA pregnancy and lactation labeling rules. Int J Women’s Dermatol. 2016;2(1):5–7. https://doi.org/10.1016/j.ijwd.2015.12.005.
Lowe NJ, Rizk D, Grimes P, Billips M, Pincus S. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther. 1998;20(5):945–59. https://doi.org/10.1016/s0149-2918(98)80076-3.
Chien AL, Qi J, Rainer B, Sachs DL, Helfrich YR. Treatment of acne in pregnancy. J Am Board of Family Med JABFM. 2016;29(2):254–62. https://doi.org/10.3122/jabfm.2016.02.150165.
Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70(3):401.e1-415. https://doi.org/10.1016/j.jaad.2013.09.010.
Trivedi NA. A meta-analysis of low-dose aspirin for prevention of preeclampsia. J Postgrad Med. 2011;57(2):91–5. https://doi.org/10.4103/0022-3859.81858.
Tuffanelli DL. Successful pregnancy in a patient with dermatitis herpetiformis treated with low-dose dapsone. Arch Dermatol. 1982;118(11):876.
Kraeling ME, Bronaugh RL. In vitro percutaneous absorption of alpha hydroxy acids in human skin. J Soc Cosmet Chem. 1997;48:187–97.
Munley SM, Kennedy GL, Hurtt ME. Developmental toxicity study of glycolic acid in rats. Drug Chem Toxicol. 1999;22(4):569–82. https://doi.org/10.3109/01480549908993168.
Peterson H, Kircik L, Armstrong AW. Individual article: clascoterone cream 1%: mechanism of action, efficacy, and safety of a novel, first-in-class topical antiandrogen therapy for acne. J Drugs Dermatol. 2023;22(6):SF350992s7-SF350992s14.
Panchaud A, Csajka C, Merlob P, Schaefer C, Berlin M, De Santis M, Vial T, Ieri A, Malm H, Eleftheriou G, Stahl B, Rousso P, Winterfeld U, Rothuizen LE, Buclin T. Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study. J Clin Pharmacol. 2012;52(12):1844–51. https://doi.org/10.1177/0091270011429566.
Shapiro L, Pastuszak A, Curto G, Koren G. Safety of first-trimester exposure to topical tretinoin: prospective cohort study. Lancet (London, England). 1997;350(9085):1143–4. https://doi.org/10.1016/S0140-6736(05)63790-7.
Weiss J, Mallavalli S, Meckfessel M, Griffin S, Wagner N. Safe use of adapalene 0.1% gel in a non-prescription environment. J Drugs iDermatol JDD. 2021;20(12):1330–5. https://doi.org/10.36849/jdd.6527.
Highlights of Prescribing DIFFERIN (adapelene) Gel, 0.3%. (n.d.). Retrieved November 16, 2023, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021753s002lbl.pdf. Accessed on 10 Dec 2023.
Adapalene Cream, 0.1%. (n.d.). Dailymed.nlm.nih.gov. Retrieved November 16, 2023, from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94cf9af1-afab-4064-a2ca-619b54218262&type=display. Accessed on 10 Dec 2023.
Han G, Wu JJ, Del Rosso JQ. Use of topical tazarotene for the treatment of acne vulgaris in pregnancy: a literature review. J Clin Aesth Dermatol. 2020;13(9):E59–65.
Lin KJ, Mitchell AA, Yau WP, Louik C, Hernández-Díaz S. Maternal exposure to amoxicillin and the risk of oral clefts. Epidemiology. 2012;23(5):699–705. https://doi.org/10.1097/EDE.0b013e318258cb05.
Hale EK, Pomeranz MK. Dermatologic agents during pregnancy and lactation: an update and clinical review. Int J Dermatol. 2002;41(4):197–203. https://doi.org/10.1046/j.1365-4362.2002.01464.x.
Cooper WO, Griffin MR, Arbogast P, Hickson GB, Gautam S, Ray WA. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med. 2002;156(7):647–50. https://doi.org/10.1001/archpedi.156.7.647.
Awan SZ, Lu J. Management of severe acne during pregnancy: A case report and review of the literature. Int J women’s Dermatol. 2017;3(3):145–50. https://doi.org/10.1016/j.ijwd.2017.06.001.
Forestiero V, Sconfienza E, Mulatero P, Monticone S. Primary aldosteronism in pregnancy. Rev Endocr Metab Disord. 2023;24(1):39–48. https://doi.org/10.1007/s11154-022-09729-6.
Dréno B, Blouin E. Acné de la femme enceinte et sels de zinc: revue de la littérature [Acne, pregnant women and zinc salts: a literature review]. Ann Dermatol Venereol. 2008;135(1):27–33. https://doi.org/10.1016/j.annder.2007.07.001.
Grzeszczak K, Kwiatkowski S, Kosik-Bogacka D. The role of Fe, Zn, and Cu in PRegnancy. Biomolecules. 2020;10(8):1176. https://doi.org/10.3390/biom10081176.
Yee BE, Richards P, Sui JY, Marsch AF. Serum zinc levels and efficacy of zinc treatment in acne vulgaris: A systematic review and meta-analysis. Dermatol Ther. 2020;33(6): e14252. https://doi.org/10.1111/dth.14252.
Miller RK, Hendrickx AG, Mills JL, Hummler H, Wiegand UW. Periconceptional vitamin A use: how much is teratogenic? Reprod Toxicol (Elmsford, NY). 1998;12(1):75–88. https://doi.org/10.1016/s0890-6238(97)00102-0.
Zamil DH, Burns EK, Perez-Sanchez A, Parke MA, Katta R. Risk of birth defects from vitamin A “Acne Supplements” sold online. Dermatol Pract Concept. 2021;11(3): e2021075. https://doi.org/10.5826/dpc.1103a75.
Trivedi MK, Kroumpouzos G, Murase JE. A review of the safety of cosmetic procedures during pregnancy and lactation. Int J Women’s Dermatol. 2017;3(1):6–10. https://doi.org/10.1016/j.ijwd.2017.01.005.
Li H, Zheng J, Wang H, Huang G, Huang Q, Feng N, Xiao J. Maternal cosmetics use during pregnancy and risks of adverse outcomes: a prospective cohort study. Sci Rep. 2019;9(1):8030. https://doi.org/10.1038/s41598-019-44546-z.
Piquero-Casals J, Morgado-Carrasco D, Rozas-Muñoz E, Mir-Bonafé JF, Trullàs C, Jourdan E, Piquero-Martin J, Zouboulis CC, Krutmann J. Sun exposure, a relevant exposome factor in acne patients and how photoprotection can improve outcomes. J Cosmet Dermatol. 2023;22(6):1919–28. https://doi.org/10.1111/jocd.15726. (Epub 2023 Mar 22 PMID: 36946555).
Gonzalez H, Farbrot A, Larkö O, Wennberg AM. Percutaneous absorption of the sunscreen benzophenone-3 after repeated whole-body applications, with and without ultraviolet irradiation. Br J Dermatol. 2006;154(2):337–40. https://doi.org/10.1111/j.1365-2133.2005.07007.x.
Putra IB, Jusuf NK, Dewi NK. Skin changes and safety profile of topical products during pregnancy. J Clin Aesth Dermatol. 2022;15(2):49–57.
Viola KV, Grant-Kels JM. Oxybenzone and pregnancy: time for more research and patient education. J Am Acad Dermatol. 2023;89(2):435–6. https://doi.org/10.1016/j.jaad.2021.11.049.
Ryu HJ, Seo MY, Jung SK, Maeng EH, Lee SY, Jang DH, Lee TJ, Jo KY, Kim YR, Cho KB, Kim MK, Lee BJ, Son SW. Zinc oxide nanoparticles: a 90-day repeated-dose dermal toxicity study in rats. Int J Nanomed. 2014;9 Suppl 2(Suppl 2):137–44. https://doi.org/10.2147/IJN.S57930.
Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet (London, England). 1993;341(8854):1181–2. https://doi.org/10.1016/0140-6736(93)91004-6.
Loureiro KD, Kao KK, Jones KL, Alvarado S, Chavez C, Dick L, Felix R, Johnson D, Chambers CD. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A. 2005;136(2):117–21. https://doi.org/10.1002/ajmg.a.30744.
Kaplan YC, Ozsarfati J, Etwel F, Nickel C, Nulman I, Koren G. Pregnancy outcomes following first-trimester exposure to topical retinoids: a systematic review and meta-analysis. Br J Dermatol. 2015;173(5):1132–41. https://doi.org/10.1111/bjd.14053.
Horne HW Jr, Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies: a prospective study. Int J Fertil. 1980;25(4):315–7.
Baldwin HE. Treating acne during pregnancy and lactation. Cutis. 2015;96(1):11–2.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding Sources
None.
Conflict of Interest
Dr. Murase is on the speakers board for Non-Branded Disease State Management Talks for UCB and Regeneron, has served on advisory boards for Sanofi-Regeneron and Bristol-Myers Squibb, and has provided dermatological consulting services for UCB, AbbVie, and UpToDate. Dr. Keri and Mr. Rau have no conflicts to declare.
Ethics Approval
Institutional review board approval status: Exempt.
Author Contributions
The first draft of the manuscript was written by AR, and critical revisions were done by JK and JM. All authors read and approved the final manuscript.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Rau, A., Keri, J. & Murase, J.E. Management of Acne in Pregnancy. Am J Clin Dermatol (2024). https://doi.org/10.1007/s40257-024-00851-6
Accepted:
Published:
DOI: https://doi.org/10.1007/s40257-024-00851-6